血液腫瘤科

Medicine & Life Sciences

1. Neoplasms 100%
2. Apoptosis 72%
3. Taiwan 71%
4. Breast Neoplasms 70%
5. Solanum nigrum 66%
6. Drug Therapy 56%
7. Neoplasm Metastasis 51%
8. Colorectal Neoplasms 48%
9. Cellular Apoptosis Susceptibility Protein 47%
10. Hepatocellular Carcinoma 46%
11. Cisplatin 42%
12. Therapeutics 41%
13. glucose-regulated proteins 39%
14. Survival 38%
15. Propensity Score 37%
16. Adenocarcinoma of Lung 35%
17. Doxorubicin 32%
18. Autophagy 31%
19. Lung Neoplasms 30%
20. Chemoradiotherapy 29%
21. Cell Death 29%
22. Mouth Neoplasms 29%
23. Extracellular Signal-Regulated MAP Kinases 27%
24. Epithelial-Mesenchymal Transition 27%
25. Adenocarcinoma 27%
26. Cohort Studies 26%
27. Prostatic Neoplasms 26%
28. Non-Small Cell Lung Carcinoma 25%
29. honokiol 25%
30. Radiotherapy 24%
31. Myeloid Cells 24%
32. Reactive Oxygen Species 23%
33. Fluorouracil 23%
34. Luteolin 22%
35. tricetin 22%
36. Cell Movement 22%
37. HL-60 Cells 22%
38. Docetaxel 22%
39. Avemar 21%
40. Pancreatic Neoplasms 21%
41. Chromosome Segregation 20%
42. gemcitabine 19%
43. Population 19%
44. Uterine Cervical Neoplasms 19%
45. Carcinoma 19%
46. JNK Mitogen-Activated Protein Kinases 19%
47. Adjuvant Chemotherapy 19%
48. Quality of Life 18%
49. Quercetin 18%
50. Acute Myeloid Leukemia 17%
51. Drug Resistance 17%
52. Catenins 17%
53. SERPIN-B5 17%
54. Ovarian Neoplasms 16%
55. Heterografts 16%
56. Growth 16%
57. Caspase 8 16%
58. Glioblastoma 16%
59. MAP Kinase Signaling System 16%
60. Protein-Tyrosine Kinases 15%
61. Stomach Neoplasms 15%
62. Recurrence 15%
63. Caspase 3 15%
64. Colonic Neoplasms 15%
65. Neoplastic Stem Cells 15%
66. Cell Cycle Checkpoints 15%
67. Confidence Intervals 15%
68. Mefloquine 15%
69. Phosphotransferases 14%
70. Chinese Traditional Medicine 14%
71. Staining and Labeling 14%
72. Cell Cycle Resting Phase 14%
73. Complementary Therapies 14%
74. Cell Line 14%
75. Esophageal Squamous Cell Carcinoma 14%
76. Cell Cycle 14%
77. Computational Biology 14%
78. Chronic Pain 14%
79. Pharmaceutical Preparations 14%
80. Azacitidine 14%
81. Thrombomodulin 14%
82. Liver 14%
83. Camptothecin 13%
84. Intensity-Modulated Radiotherapy 13%
85. Decitabine 13%
86. Hep G2 Cells 13%
87. Caspases 13%
88. Flavonoids 13%
89. G1 Phase 13%
90. Cetuximab 13%
91. Cell Proliferation 13%
92. Esophageal Neoplasms 13%
93. Fish Oils 13%
94. Sorafenib 13%
95. Bone Neoplasms 13%
96. Genes 13%
97. Paris 12%
98. Yang Deficiency 12%
99. Leukemia 12%
100. Genomics 12%